Vertex Pharmaceuticals is focused on discovering medicines for people with serious diseases. Developing innovative medicines requires carefully designed studies in humans that evaluate the safety and efficacy of an investigational medicine.
Vertex is conducting trials in the following areas: Alpha 1-antitrypsin deficiency, APOL1-mediated kidney disease, beta-thalassemia, cystic fibrosis, pain, sickle cell disease and type 1 diabetes. If you’re interested in a Vertex clinical trial, we encourage you to speak with your physician about what might be involved and your eligibility.
Our commitment to clinical trial diversity
Clinical trials should be representative of all people living with a specific disease. Ensuring appropriate diversity in participant characteristics helps Vertex to develop and deliver innovative medicines that can make a meaningful difference in the lives of all people living with that disease. Vertex recognizes that individuals may respond differently to a given treatment based on their age, biological sex, weight, race, ethnicity, geography and other factors. By providing equitable access to and including people from diverse backgrounds and locations, clinical trials can show if the potential treatments are safe and effective across patient populations. Vertex's aim is to sponsor inclusive clinical trials that represent the diversity of people living with the disease.
Our commitment to transparency
Vertex is committed to advancing medicine and improving patients' lives. This includes the responsible sharing of clinical trial data with qualified researchers.
A scientific board reviews all proposals for the use of data. Proposals are reviewed for the nature of the request, the merit of the research proposed, and the intended use of the data. Approvals are at the discretion of Vertex.
If you are a qualified researcher interested in submitting a request for Vertex clinical trial data, please submit your proposal here.